Clarient, Acorn strike research deal for molecular tumor tests

Under the agreement, a standardized testing protocol across the Acorn network of oncology community will be set up, providing treatment guidelines and clinical trial opportunities.

The process is believed to bring improvements in oncology treatment and research that focuses on delivering targeted treatments based on the specific genetic markers for each patient.

In addition, the deal will establish a system for the collection of a broad array of tumor-specific biomarker data at the time of the patient’s initial cancer diagnosis.

Clarient’s expertise in cancer diagnostics and Acorn’s oncology network and advanced bioinformatics platform, will enable in better determination of an effective treatment regimen for the patient’s tumor-specific biomarker profile.